CAJ | 학술논문

目的：探讨不同剂量瑞舒伐他汀对急性冠脉综合征(ACS)非经皮冠状动脉介入(PCI)药物保守治疗患者血清铁蛋白、血脂水平及炎性因子的影响。方法120例ACS患者随机分为A、B、C三组,各40例,在给予吸氧、抗凝、扩张冠脉血管等治疗的基础上, A组口服瑞舒伐他汀10 mg/d, B组口服瑞舒伐他汀20 mg/d, C组口服阿托伐他汀钙20 mg/d。治疗前和治疗16周后抽取静脉血,观察三组治疗前后血清铁蛋白、血清低密度脂蛋白(LDL)、氧化型低密度脂蛋白(oxLDL)、超敏C反应蛋白(hs-CRP)水平。结果三组患者治疗16周后血清铁蛋白、血清LDL、oxLDL、hs-CRP水平均较治疗前明显降低(P<0.05)；其中B组较A、C组降低明显(P<0.05)；A组与C组比较差异无统计学意义(P>0.05)。结论 ACS非PCI药物保守治疗患者早期使用不同剂量瑞舒伐他汀能明显降低血清铁蛋白、血清LDL、oxLDL、hs-CRP水平,降低血脂水平,降低炎性因子,减轻炎性反应,能起到稳定斑块、抗栓、改善预后的作用。
목적：탐토불동제량서서벌타정대급성관맥종합정(ACS)비경피관상동맥개입(PCI)약물보수치료환자혈청철단백、혈지수평급염성인자적영향。방법120례ACS환자수궤분위A、B、C삼조,각40례,재급여흡양、항응、확장관맥혈관등치료적기출상, A조구복서서벌타정10 mg/d, B조구복서서벌타정20 mg/d, C조구복아탁벌타정개20 mg/d。치료전화치료16주후추취정맥혈,관찰삼조치료전후혈청철단백、혈청저밀도지단백(LDL)、양화형저밀도지단백(oxLDL)、초민C반응단백(hs-CRP)수평。결과삼조환자치료16주후혈청철단백、혈청LDL、oxLDL、hs-CRP수평균교치료전명현강저(P<0.05)；기중B조교A、C조강저명현(P<0.05)；A조여C조비교차이무통계학의의(P>0.05)。결론 ACS비PCI약물보수치료환자조기사용불동제량서서벌타정능명현강저혈청철단백、혈청LDL、oxLDL、hs-CRP수평,강저혈지수평,강저염성인자,감경염성반응,능기도은정반괴、항전、개선예후적작용。
Objective To explore the influence of different doses of rosuvastatin on serum ferritin, blood lipid level, and inflammatory factor in acute coronary syndrome (ACS) patients with non-percutaneous coronary intervention (PCI) medication conservative treatment.Methods A total of 120 ACS patients were randomly divided into groups A, B and C, with 40 cases in each group. On the basis of oxygen inhalation, anticoagulation, and coronary vessels expansion treatments, group A received 10 mg/d of rosuvastatin through oral administration, group B received 20 mg/d of rosuvastatin, and group C received 20 mg/d of rosuvastatin calcium. Venous blood were taken before and after 16 weeks of treatment for observation of serum ferritin, low density lipoprotein (LDL), oxidized low density lipoprotein (oxLDL), and high sensitivity C-reactive protein (hs-CRP) levels in the three groups.Results After 16 weeks of treatment, all the three groups had lowered levels of serum ferritin, LDL, oxLDL, and hs-CRP than those before treatment (P<0.05). Those decreased more obvious in group B than in groups A and C (P<0.05), and there was no statistically significant difference between group A and group C (P>0.05).Conclusion Application of different doses of rosuvastatin for ACS patients with non-PCI medication conservative treatment can reduce the levels of serum ferritin, LDL, oxLDL, hs-CRP, blood liquid, and decrease inflammatory factor and inflammatory reaction. It has effects in stabilizing plaque, anti-embolism, and improving prognosis.